Dr Susan Kay Lawson, PHD, LICSW | |
3311 Maywood Dr, Ona, WV 25545-9734 | |
(304) 962-6787 | |
Not Available |
Full Name | Dr Susan Kay Lawson |
---|---|
Gender | Female |
Speciality | Social Worker - Clinical |
Location | 3311 Maywood Dr, Ona, West Virginia |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1285677708 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
1041C0700X | Social Worker - Clinical | DP00940511 (West Virginia) | Primary |
Mailing Address | Practice Location Address |
---|---|
Dr Susan Kay Lawson, PHD, LICSW 3311 Maywood Dr, Ona, WV 25545-9734 Ph: (304) 962-6787 | Dr Susan Kay Lawson, PHD, LICSW 3311 Maywood Dr, Ona, WV 25545-9734 Ph: (304) 962-6787 |
News Archive
A new approach to defining opioid-related auto fatalities provides insight into the nature and distribution of opioid-involved deaths in the state of Maryland, say the authors of a new study led by researchers at the Johns Hopkins Bloomberg School of Public Health.
Lumbar spinal stenosis is primarily a degenerative, age-related narrowing of the lower spinal canal resulting in compression of the nerve roots. MILD treats this compression by removing small portions of lamina and hypertrophic ligamentum flavum in a minimally invasive, outpatient procedure through an opening about the size of a baby aspirin...
The usefulness of established molecular imaging/nuclear medicine approaches in identifying the hows and whys of brain dysfunction and its potential in providing immediately useful information in treating depression are emphasized in a study in the August Journal of Nuclear Medicine.
A new Commonwealth Fund survey of safety-net clinic patients in New Orleans finds that, despite being disproportionately low-income and uninsured, these patients had fewer problems affording care and fewer instances of medical debt and inefficient care than most U.S. adults.
Allos Therapeutics, Inc. has announced preliminary top line results from PROPEL, the Company's pivotal Phase 2 trial of pralatrexate (PDX) in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL), at the 50th Annual Meeting of the American Society of Hematology (abstract 261).
› Verified 5 days ago